A Randomized, Open Label, Multi-Center Phas 3 Efficacy Study of Sub-Q Abatacept in Preventing Extension of Oligoarticular JIA (Limit-JIA)

Administered By

Awarded By

Contributors

Start/End

  • June 13, 2019 - July 31, 2023